Abstract:OBJECTIVE:To evaluate the role of 2-deoxy-D-glucose (2-DG) modified supermagnetic iron oxide nanoparticles (SPIO) (γ-Fe2O3@DMSA-DG NPs) in tumor detection as a magnetic resonance imaging (MRI) contrast agent.METHODS:γ-Fe2O3@DMSA-DG NPs was prepared. The degree of A549 cells targeted absorption of γ-Fe2O3@DMSA-DG NPs was detected by Prussian blue staining, colorimetric assay, T2W and multi-echo sequence MRI. γ-Fe2O3@DMSA NPs was used as a control agent, and free D-glucose as a competitive inhibitor. Human lung adenocarcinoma A549 xenograft tumor was prepared in nude mice. Sterile aqueous suspension of γ-Fe2O3@DMSA NPs or γ-Fe2O3@DMSA-DG NPs was injected into the tail vein of nude mice. Before and 6, 12, 24, 48 h after injection, MRI imaging of the mice was performed. T2 signal intensity of the tumor, brain, liver and thigh skeletal muscles, and T2 values of the tumors were measured.RESULTS:The average diameter of the particles was about 10 nm, and there were no significant differences between the diameters of γ-Fe2O3@DMSA NPs and γ- Fe2O3@DMSA-DG NPs. The IR spectra showed the C-N retractable vibration peak at γ-Fe2O3@DMSA-DG NPs surface, indicating that 2-DG was conjugated to the γ-Fe2O3@DMSA NPs. The Prussian blue staining, colorimetric assay, MRI T2 signal intensity and T2 values revealed that γ-Fe2O3@DMSA-DG NPs were significantly more absorbed by A549 cells at growth peak than γ-Fe2O3@DMSA NPs, and the absorption of γ-Fe2O3@DMSA-DG NP was inhibited by free D-glucose. The results of in vivo examination showed that before and at 6, 12, 24, 48 h after injection of γ-Fe2O3@DMSA-DG NPs, the mean T2 signal intensities of the tumors were (326.00 ± 16.26)s, (276.40 ± 5.13)s, (268.40 ± 30.58)s, (240.40 ± 25.93)s, (262.20 ± 30.04)s, respectively, and the T2 values of the tumors were (735.80 ± 20.93) ms, (645.80 ± 69.58) ms, (615.00 ± 124.61) ms, (570.60 ± 67.78) ms, and (537.80 ± 105.29) ms, respectively. However, before and at 6, 12, 24, 48 h after injection of γ-Fe2O3@DMSA NPs, the mean T2 signal intensities of the tumors were (335.60 ± 4.93)s, (290.80 ± 5.93)s, (273.40 ± 15.08)s, (327.40 ± 16.65)s, and (313.20 ± 20.45)s, respectively, and T2 values were (686.00 ± 21.44)ms, (617.80 ± 69.93)ms, (645.20 ± 85.89)ms, (669.40 ± 13.72)ms, and (608.80 ± 61.90)ms, respectively. The T2 signal intensity and T2 value of the tumors were not declined generally after injection. The liver T2 signal intensity was decreased after injection of both γ-Fe2O3@DMSA-DG NPs and γ-Fe2O3@DMSA NPs, and T2 signal intensity of the brain and muscle did not show significant changes.CONCLUSIONS:γ-Fe2O3@DMSA-DG NPs has an ability to target glucose receptors overexpressed in tumors, and may serve as a MRI contrast agent for tumor detection.

Mri of High-Glucose Metabolism Tumors: A Study in Cells and Mice with 2-Dg-modified Superparamagnetic Iron Oxide Nanoparticles

2-Deoxy-d-glucose Modified Supermagnetic Iron Oxide Nanoparticles Enhance the Contrasting Effect on MRI of Human Lung Adenocarcinoma A549 Tumor in Nude Mice

Breast Cancer Diagnosed by MRI Using Mesoporous TiO₂-Coated (Fe₃O₄) Nanoparticles

Targeting Glut1-overexpressing MDA-MB-231 cells with 2-deoxy-d-g1ucose modified SPIOs

Detection of Human Breast Cancer Cells Using a 2-Deoxy-d-glucose-functionalized Superparamagnetic Iron Oxide Nanoparticles.

Preparation of a Glucose Receptor-Mediated Tumor Targeting 2-Dg-conjugated Superparamagnetic Iron Oxide Nanoparticles and Its in Vitro Experimental Study

Ultra-Small and Metabolizable Near-Infrared Au/Gd Nanoclusters for Targeted FL/MRI Imaging and Cancer Theranostics

2-Deoxy-d-glucose Modified Magnetic Nanoparticles with Dual Functional Properties: Nanothermotherapy and Magnetic Resonance Imaging

Biotargeting rhabdomyosarcoma A-673 cell of 2-DG modifiedsuperparamagnetic iron oxide nanoparticles with different surface coating

Preparation, Characterization of 2-Deoxy-d-glucose Functionalized Dimercaptosuccinic Acid-Coated Maghemite Nanoparticles for Targeting Tumor Cells

Specific Targeting of Breast Tumor by Octreotide-Conjugated Ultrasmall Superparamagnetic Iron Oxide Particles Using a Clinical 3.0-Tesla Magnetic Resonance Scanner

Magnetic Targeting Combined with Active Targeting of Dual-Ligand Iron Oxide Nanoprobes to Promote the Penetration Depth in Tumors for Effective Magnetic Resonance Imaging and Hyperthermia.

Enhancing MRI imaging through high loading of superparamagnetic nanogels with high sensitivity to the tumor environment

Targeted Magnetic Resonance Imaging/Near‐Infrared Dual‐Modal Imaging and Ferroptosis/Starvation Therapy of Gastric Cancer with Peritoneal Metastasis

Gd(3+)-DTPA-DG: novel nanosized dual anticancer and molecular imaging agent

Biocompatibility and proteomic profiling of DMSA-coated iron nanocubes in a human glioblastoma cell line

Deuterium MRSI characterizations of glucose metabolism in orthotopic pancreatic cancer mouse models

Targeted Dual-Contrast T1- and T2-weighted Magnetic Resonance Imaging of Tumors Using Multifunctional Gadolinium-Labeled Superparamagnetic Iron Oxide Nanoparticles

Magnetic Resonance Imaging of Glioma with Novel APTS-coated Superparamagnetic Iron Oxide Nanoparticles

A Functional Iron Oxide Nanoparticles Modified with PLA-PEG-DG As Tumor-Targeted MRI Contrast Agent

Specific Targeting of Gliomas with Multifunctional Superparamagnetic Iron Oxide Nanoparticle Optical and Magnetic Resonance Imaging Contrast Agents